If you or a loved one has experienced persistent nausea, vomiting, or abdominal pain while taking Ozempic, you may be concerned about gastroparesis. The legacy of medical information has long provided a foundation for understanding drug risks, and this page examines the FDA label context for Ozempic in Arizona, including what the agency has communicated about this potential side effect.
Gastroparesis is a chronic disorder characterized by delayed gastric emptying in the absence of mechanical obstruction, leading to symptoms such as nausea, vomiting, early satiety, bloating, and abdominal pain. Diagnosis typically involves gastric emptying scintigraphy, which measures the rate at which food leaves the stomach. The condition can significantly impair quality of life and may require dietary modifications, medications, or even surgical interventions. Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for the management of type 2 diabetes. Its pharmacology involves slowing gastric emptying, which contributes to its glucose-lowering effects. However, this mechanism also underlies a range of gastrointestinal adverse reactions. In placebo-controlled trials, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic than placebo (placebo 15.3%, Ozempic 0.5 mg 32.7%, Ozempic 1 mg 36.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation. More patients receiving Ozempic 0.5 mg (3.1%) and Ozempic 1 mg (3.8%) discontinued treatment due to gastrointestinal adverse reactions than patients receiving placebo (0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In a trial with Ozempic 1 mg and 2 mg, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic 2 mg (34.0%) vs Ozempic 1 mg (30.8%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Additional gastrointestinal adverse reactions with a frequency of less than 5% associated with Ozempic include dyspepsia (placebo 1.9%, 0.5 mg 3.5%, 1 mg 2.7%), eructation (0%, 2.7%, 1.1%), flatulence (0.8%, 0.4%, 1.5%), gastroesophageal reflux disease (0%, 1.9%, 1.5%), and gastritis (0.8%, 0.8%, 0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). While gastroparesis is not explicitly listed in these clinical trial data, the slowing of gastric emptying is a known pharmacodynamic effect of GLP-1 receptor agonists, and persistent or severe gastrointestinal symptoms may be indicative of gastroparesis in susceptible individuals.
Mechanistic pathways linking Ozempic to gastroparesis involve the drug's action on GLP-1 receptors in the gastrointestinal tract, which inhibits gastric motility and delays gastric emptying. In patients with pre-existing gastric dysmotility or those who develop severe symptoms, this effect can lead to clinical gastroparesis. The timeline between exposure and documented harm can vary; symptoms often emerge during dose escalation but may persist or worsen with continued use. The adequacy of warnings regarding Ozempic and gastroparesis is a critical risk anchor. The prescribing information for Ozempic includes warnings about gastrointestinal adverse reactions, but it does not specifically mention gastroparesis as a potential adverse effect. The label notes that serious hypersensitivity reactions have been reported, including anaphylaxis and angioedema, and advises caution in patients with a history of such reactions to other GLP-1 receptor agonists (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). However, the absence of a specific warning for gastroparesis may raise questions about whether patients and healthcare providers were adequately informed of this risk.
For affected patients in Arizona, settlement-related considerations must account for the statute of limitations, which governs the time frame within which a lawsuit can be filed. In Arizona, the statute of limitations for personal injury claims, including those related to pharmaceutical products, is generally two years from the date the injury is discovered or reasonably should have been discovered. This timeline is critical for patients who developed gastroparesis after using Ozempic. The date of discovery may be when a physician diagnoses gastroparesis and links it to Ozempic use, or when the patient becomes aware of the potential connection. Given that gastrointestinal symptoms can be common and may not immediately raise suspicion of gastroparesis, the discovery date can be complex. Patients should seek legal counsel promptly to ensure their claims are filed within the applicable limitations period. Settlement considerations also involve the strength of evidence linking Ozempic to gastroparesis, the severity of the patient's condition, and the adequacy of warnings. The clinical trial data show a clear increase in gastrointestinal adverse reactions with Ozempic, but the specific diagnosis of gastroparesis is not captured in those data. This may affect the ability to establish causation in individual cases. However, the mechanistic plausibility and the drug's known effect on gastric emptying support a potential link. The timeline between exposure and harm is also relevant; patients who developed symptoms shortly after starting Ozempic and had no prior history of gastroparesis may have stronger claims. In summary, patients in Arizona who have developed gastroparesis after using Ozempic should be aware of the statute of limitations and seek legal advice to evaluate their options. The evidence from clinical trials indicates a higher incidence of gastrointestinal adverse reactions with Ozempic, but the specific risk of gastroparesis is not explicitly addressed in the prescribing information. This gap in warnings may be a factor in settlement negotiations. Patients should document their symptoms, diagnosis, and timeline of Ozempic use to support any potential claim.
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
In Arizona, the statute of limitations for personal injury claims, including those related to pharmaceutical products, is generally two years from the date the injury is discovered or reasonably should have been discovered. For Ozempic-related gastroparesis, this means the clock starts when a physician diagnoses gastroparesis and links it to Ozempic use, or when the patient becomes aware of the potential connection. It is crucial to seek legal counsel promptly to ensure your claim is filed within this timeframe.
The prescribing information for Ozempic includes warnings about gastrointestinal adverse reactions such as nausea, vomiting, and diarrhea, but it does not specifically mention gastroparesis as a potential adverse effect. This absence of a specific warning may be a factor in settlement negotiations, as it raises questions about whether patients and healthcare providers were adequately informed of the risk of gastroparesis.
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.
Individuals with documented Ozempic exposure and a related diagnosis may request an independent, no-cost eligibility review.
Request archival records or inquire about member-exclusive transition and benefit programs.